Nivolumab plus chemotherapy improves pathological complete response in resectable NSCLC with PD-L1 < 1%Nivolumab plus chemotherapy improves pathological response in certain lung cancers

This network meta-analysis evaluated the efficacy of various neoadjuvant chemoimmunotherapy regimens compared to chemotherapy alone in a population of 1012 patients with resectable non-small cell lung cancer (NSCLC) and low PD-L1 expression (< 1%). The study aimed to determine if adding immunotherapy to standard neoadjuvant chemotherapy improved pathological outcomes or survival metrics for this specific patient subgroup.

The primary investigation focused on four key clinical endpoints: event-free survival, overall survival, pathological complete response (pCR), and major pathological response (mPR). These measures were compared across various chemoimmunotherapy regimens against a control group receiving chemotherapy alone. The analysis specifically targeted the subset of patients with PD-1 expression less than 1%, a population often challenging to treat with monotherapy.

Regarding survival outcomes, the data indicated that no chemoimmunotherapy regimen significantly improved event-free survival when compared with chemotherapy alone. Similarly, no chemoimmunotherapy regimen was found to significantly improve overall survival over the chemotherapy-only control group. These findings suggest that while adding immunotherapy may alter the local tumor environment, it did not translate into a statistically significant survival advantage in this specific cohort.

In contrast, the results for pathological response showed more distinct differences. Nivolumab plus chemotherapy was identified as the only regimen associated with a statistically significant improvement in pathological complete response compared to chemotherapy alone. The reported effect size for this finding was an odds ratio of 5.88 (95% credible interval 1.41-37.4). This suggests a substantial increase in the likelihood of achieving a complete pathological response when nivolumab is added to neoadjuvant chemotherapy.

For the secondary outcome of major pathological response, the analysis found that no regimen significantly improved major pathological response compared to chemotherapy alone. While the pCR data showed a significant signal for nivolumab, this did not extend to the broader mPR category in this specific meta-analysis. Safety and tolerability data, including specific adverse event rates or discontinuation frequencies, were not reported in the provided evidence.

Methodologically, the study noted that evidence for many of the regimens analyzed was derived from subgroup analyses, which can introduce variability in interpretation. The results are specifically applicable to patients with PD-L1 expression < 1%. These findings contrast with general expectations that any improvement in pathological response automatically correlates with survival benefits; here, only nivolumab showed a significant impact on pCR.

Clinically, these results suggest that for patients with resectable NSCLC and low PD-L1 expression, the addition of nivolumab to neoadjuvant chemotherapy may be an effective strategy to achieve pathological complete response. However, clinicians should note that this improvement in local pathology has not been shown to translate into improved event-free survival or overall survival at this time. The lack of significant difference in major pathological response suggests a specific benefit for pCR with nivolumab.

Several questions remain regarding the long-term implications of these findings. It is unclear if the higher rate of pathological complete response with nivolumab leads to different long-term outcomes compared to a major pathological response. Additionally, since many regimens were evaluated via subgroup analyses, further large-scale trials are needed to confirm the specific benefits of various chemoimmunotherapy combinations in the PD-L1 < 1% population.